Therapeutic Potential of Targeting Interleukin 5 in Asthma

Research output: Contribution to journalLiterature review

6 Citations (Scopus)

Abstract

It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of interleukin (IL)-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were, for the most part, disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review summarises the current evidence, demonstrating the effectiveness or otherwise of the targeting of IL-5 in patients with asthma.
Original languageEnglish
Pages (from-to)559-563
Number of pages5
JournalBioDrugs
Volume27
Issue number6
Early online date1 Jun 2013
DOIs
Publication statusPublished - 1 Dec 2013

Fingerprint

Interleukin-5
Asthma
Biological Products
Therapeutics
Interleukin-13
Interleukin-4
Animal Models
Biomarkers
Clinical Trials
Cytokines
Inflammation
Phenotype
Lung
Population

Cite this

Therapeutic Potential of Targeting Interleukin 5 in Asthma. / Walsh, Garry M.

In: BioDrugs, Vol. 27, No. 6, 01.12.2013, p. 559-563.

Research output: Contribution to journalLiterature review

@article{d1c65a336170455c8de1633470882867,
title = "Therapeutic Potential of Targeting Interleukin 5 in Asthma",
abstract = "It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of interleukin (IL)-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were, for the most part, disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review summarises the current evidence, demonstrating the effectiveness or otherwise of the targeting of IL-5 in patients with asthma.",
author = "Walsh, {Garry M.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s40259-013-0047-0",
language = "English",
volume = "27",
pages = "559--563",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Therapeutic Potential of Targeting Interleukin 5 in Asthma

AU - Walsh, Garry M.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of interleukin (IL)-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were, for the most part, disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review summarises the current evidence, demonstrating the effectiveness or otherwise of the targeting of IL-5 in patients with asthma.

AB - It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of interleukin (IL)-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were, for the most part, disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review summarises the current evidence, demonstrating the effectiveness or otherwise of the targeting of IL-5 in patients with asthma.

U2 - 10.1007/s40259-013-0047-0

DO - 10.1007/s40259-013-0047-0

M3 - Literature review

VL - 27

SP - 559

EP - 563

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 6

ER -